Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis.

What was studied

This phase 3 trial compared R2 with R-Chemo in untreated advanced follicular lymphoma. R2 is rituximab plus lenalidomide. R-Chemo is rituximab with chemotherapy. It was a multinational trial. In all, 1030 people were randomized. This is the final analysis, at 120 months.

What they found

Median progression-free survival was close in both arms. It was 110.6 months with R2 and 102.8 months with R-Chemo. An independent review committee judged progression. The 10-year progression-free rates were also close in both arms. Median overall survival was not reached in either arm. The 10-year survival rates were close as well. People whose disease progressed within 24 months did worse. The hazard ratio was 6.215. On this, no difference was seen between the study groups. Second primary cancers occurred at 2.11 cases per 100 patient-years. Only 9 transformations occurred after 24 months. In each group, 87 people died, mainly from lymphoma progression and second cancers.

What it means for patients

The authors say the long follow-up confirms that R2 gives a chemotherapy-free alternative. It is an alternative to immunochemotherapy in these patients.

Why it is not certain yet

The abstract gives no test result for the progression-free comparison. It does not report side effects beyond second cancers and transformations. Median overall survival was still not reached at this analysis.

Source

Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis.

We restate facts from the source record in our own words. The original wording belongs to its publisher.